Summary of Precigen's Presentation at the J.P. Morgan Healthcare Conference Company Overview - **Company**: Precigen - **Industry**: Biotechnology, focusing on cell and gene therapy for rare diseases and oncology - **Location**: Maryland, USA - **Key Product**: Pepcimeus, an FDA-approved drug for recurrent respiratory papillomatosis (RRP) [2][9] Core Points and Arguments Advancements in Technology and Product Development - Precigen utilizes a differentiated adenovirus platform, specifically gorilla adenoviral vectors, which have a payload capacity of 12 to 15 kb, allowing for more genes to be delivered compared to traditional adenoviruses [3][4] - The platform enables repeat dosing without the high titers of neutralizing antibodies that typically inhibit efficacy in other adenoviral vectors, promoting T cell immunity [5][6] - Pepcimeus was developed and received FDA approval in just four years, showcasing the efficiency of Precigen's development process [3][9] Clinical Data and Patient Impact - Pepcimeus is the first FDA-approved therapy for RRP, a condition caused by HPV 6 and 11, leading to benign tumors in the respiratory tract [10][12] - Clinical trials showed that patients who previously underwent multiple surgeries experienced significant reductions in surgical needs after receiving Pepcimeus [15][16] - The drug is administered subcutaneously, similar to a flu vaccine, making it easy for patients to receive [13][14] Market Potential and Commercialization Strategy - The U.S. market for RRP is estimated at 27,000 patients, with potential expansion to 35,000 patients in Europe and 85,000 in China [17][22] - Precigen has secured coverage for Pepcimeus through Medicare, Medicaid, and over 170 million lives across various private health insurances, achieving nearly 80% coverage within a quarter of launch [19][37] - The company has established a patient support hub, which has seen rapid growth in patient enrollment, indicating strong market interest [20][21] Future Plans and Regulatory Strategy - Precigen plans to expand Pepcimeus' indications to pediatric patients and is pursuing regulatory approval in the EU and Japan [23][24] - The company aims to leverage its adenovirus platform for additional indications, including HPV-related cancers, with ongoing Phase 2 trials [24][25] Additional Important Insights - The transition from surgical to medical management of RRP represents a significant shift in treatment paradigms, with the potential to improve patient outcomes and reduce the need for invasive procedures [31][32] - Precigen's leadership team has demonstrated expertise in navigating the complexities of drug development and commercialization, contributing to the company's rapid progress since its inception in 2020 [25][26] - The company is focused on establishing partnerships for international expansion while maintaining a primary focus on the U.S. market [39][40]

Summary of Canaan Inc. Conference Call Company Overview - **Company Name**: Canaan Inc. - **Ticker**: CAN - **IPO Year**: 2019 - **Industry**: Cryptocurrency and Bitcoin mining equipment manufacturing - **Headquarters**: Singapore - **Employee Count**: Over 20 in the U.S. as of 2021, with operations in various states [4][5] Key Financial Highlights - **Q3 Revenue**: $150 million, exceeding guidance of $125-$145 million - **Year-over-Year Revenue Growth**: 104% - **Quarter-over-Quarter Revenue Growth**: 50% - **Gross Profit**: $16.6 million, representing 79% quarter-over-quarter growth - **Operating Loss**: Narrowed to $23.9 million - **Bitcoin Treasury**: 1,610 Bitcoins as of October 30th, 2025 - **Average Selling Price for Machines**: $11.80 per terahash per second - **Fourth Quarter Revenue Guidance**: $175 million - $205 million [13][14][29] Product and Market Position - **ASIC Development**: Developed 16 generations of ASICs, leading to high efficiency and computing power [7][8] - **Market Share**: Positioned as the second provider in terms of hash rate delivered, gaining market share due to durable machines and transparency as a public company [41] - **Sales Channels**: Products sold in 86 countries through online and offline channels [10] - **Self-Mining Operations**: Generated revenue from both machine sales and self-mining, with a self-mining gross margin of 26.3% [10][20] Strategic Initiatives - **Vertical Integration**: Focus on ASIC design, manufacturing, and self-mining to manage inventory and cash flow [10][12] - **HODL Policy**: Bitcoin mined is used to cover expenses, with the remainder held on the balance sheet [11][25] - **Joint Ventures**: Collaborations with third parties for self-mining operations, including a 20-megawatt hosting agreement in Texas [25][26] - **Sustainability Initiatives**: Projects like gas-to-computing pilot in Alberta and greenhouse heating solutions to recycle heat from mining operations [21][27] Industry Dynamics - **Regulatory Environment**: The current regulatory landscape is more favorable compared to the time of the IPO [4] - **Market Competition**: Increasing competition in the Bitcoin mining market, with a focus on maintaining operational efficiency and customer relationships [22][36] - **Power Market Trends**: The shift towards AI data centers may impact Bitcoin mining power availability, but mining operations have established relationships with power providers [36][40] Risks and Challenges - **Tariff Risks**: Potential changes in tariffs could impact competitiveness, but U.S. manufacturing helps mitigate these risks [13][33] - **Market Volatility**: Bitcoin price fluctuations can affect mining profitability and operational decisions [22][39] Additional Insights - **Customer Preferences**: U.S. customers prefer machines assembled in the U.S. to avoid tariff issues [13][34] - **Home Mining Solutions**: Introduction of consumer-friendly mining equipment aimed at individual users and small businesses [15][19] - **Future Outlook**: Anticipation of continued growth in Bitcoin mining and machine sales, with a focus on innovation and sustainability [24][27] This summary encapsulates the key points discussed during the conference call, highlighting Canaan Inc.'s financial performance, strategic initiatives, market position, and industry dynamics.

Financial Performance and Growth - Clover Health is positioned for 2026 GAAP Net Income profitability [9] - The company anticipates a greater than $70 Per Member Per Month (PMPM) revenue tailwind from a 4-Star rating and favorable rate update [26] - Clover Health experienced a +53% year-over-year (YoY) growth in Medicare Advantage membership, up from +27% in 2025 [11] - Clover Health expects to deliver FY26 GAAP Net Income Profitability, benefiting from 4 Stars, strong retention, stable benefits, and industry pullback [47] Clinical Model and Technology - Clover Assistant (CA) is a key component, with models trained to support improved clinical outcomes [20] - Counterpart Health (CPH) is rapidly expanding with +450% YoY customer users, scaling alongside the growing MA profit engine [37] - Clover Health's Medicare Advantage PPO plans received a score of 4.72 out of 5 Stars on HEDIS for the Plan Year 2026 [38] - Clover Assistant use is correlated with improved medication adherence, with medication fills increased by ~5% on the day of the Clover Assistant visit [118] Market and Strategy - Clover Health is focused on strategic market-leading growth [18] - The company is targeting sustained Adjusted EBITDA profitability [11] - Approximately 97% of members are in current 4 Star payment year PPO [11]

Financial Data and Key Metrics Changes - Net earnings for the first quarter rose to $7.6 million or $0.39 per share, compared to $1.1 million or $0.06 per share in the same period last year [5] - Gross profit improved to $18.1 million from $9.5 million a year ago, with gross margin expanding to 11.3% from 7.3% [8] - SG&A expenses increased to $8.8 million, or 5.5% of net sales, compared to $7.9 million, or 6.1% of net sales, in the prior year [8][9] - Effective tax rate decreased to 21% from 26.1% in the prior year [9] Business Line Data and Key Metrics Changes - First quarter shipments increased by 3.8% year-over-year, reflecting improved demand across commercial and infrastructure markets [5][6] - Average selling prices increased by 18.8% year-over-year due to pricing actions taken to offset higher steel wire rod costs [6] Market Data and Key Metrics Changes - The Architecture Billings Index (ABI) registered 45.3, indicating a contraction in non-residential commercial construction activity for 13 consecutive months [12] - The Dodge Momentum Index rose 7% in December, with a year-over-year increase of 50%, indicating strengthening activity in commercial planning [13] Company Strategy and Development Direction - The company is optimistic about 2026, driven by demand from the Infrastructure Investment and Jobs Act (IIJA) and data center construction [3][16] - The company plans to invest approximately $20 million in capital expenditures to support growth and reduce production costs [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledges uncertainties due to trade policies and economic conditions but remains confident in demand trends and customer conversations [14][16] - The company expects to continue importing raw materials until domestic availability improves, impacting net working capital [22][23] Other Important Information - The company returned $19.4 million to shareholders through a special cash dividend and continued share buybacks [12] - Cash flow from operations used $700,000 in the quarter, compared to providing $19 million last year, primarily due to increased inventories [10] Q&A Session Summary Question: Can you provide more details on commitments related to data center projects? - Management noted that the data center business is new but is seeing repeat opportunities and robust demand [27] Question: How have wire rod constraints affected volumes? - Management explained that inventory growth was due to insufficient domestic wire rod supply, necessitating offshore purchases [29] Question: Are you realizing SG&A leverage from recent acquisitions? - Management confirmed that synergies from acquisitions are being realized, contributing to improved performance [31] Question: What has allowed the company to grow despite industry headwinds? - Management attributed growth to internal factors such as work in the cast-in-place market and acquisitions [38] Question: What is the outlook for the residential market? - Management indicated that any meaningful impact from the residential market is unlikely for 2026 [45] Question: How are labor costs being managed? - Management acknowledged upward pressure on labor costs and inflationary impacts on operations [46]

Bank7 (NasdaqGS:BSVN) Q4 2025 Earnings call January 15, 2026 10:00 AM ET Company ParticipantsWoodrow Lay - Managing DirectorThomas L. Travis - President and CEOJordan Ghent - Research AssociateKelly Harris - CFOJason Estes - EVP and COOConference Call ParticipantsNathan Race - AnalystOperatorWelcome to the Bank7 Corp. Fourth Quarter and Year 2025 Earnings Call. Before we get started, I'd like to highlight the legal information and disclaimer on page 27 of the investor presentation. For those who do not have ...

Bank7 (NasdaqGS:BSVN) Q4 2025 Earnings call January 15, 2026 10:00 AM ET Company ParticipantsWoodrow Lay - Managing DirectorThomas L. Travis - President and CEOJordan Ghent - Research AssociateKelly Harris - CFOJason Estes - EVP and COOConference Call ParticipantsNathan Race - AnalystOperatorWelcome to the Bank7 Corp. Fourth Quarter and Year 2025 Earnings Call. Before we get started, I'd like to highlight the legal information and disclaimer on page 27 of the investor presentation. For those who do not have ...

Financial Data and Key Metrics Changes - The meeting discussed the approval of the Continuance Resolution and Domestication Resolution, which were passed by a majority of not less than two-thirds of the votes cast [19] - The 2026 Incentive Award Plan was also approved by a majority of the votes cast [19] Business Lines Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided during the meeting Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting Company Strategy and Development Direction - The company is transitioning from Alberta to British Columbia and then domesticate to Nevada, indicating a strategic shift in its operational base [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted virtually, ensuring shareholder rights were protected and allowing participation similar to in-person meetings [3][4] - The voting results will be filed on SEDAR and made available on the company's website [20] Q&A Session Summary - No specific questions were raised during the meeting regarding the motions presented [12][15][18][22]

Financial Data and Key Metrics Changes - The meeting discussed the approval of the Continuance Resolution and Domestication Resolution, which were passed by a majority of not less than 2/3 of the votes cast [19] - The 2026 Incentive Award Plan also received majority approval from the votes cast [19] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were provided during the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company is transitioning from Alberta to British Columbia and then to Nevada, indicating a strategic move to potentially enhance operational flexibility and regulatory advantages [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted virtually, ensuring shareholder rights were protected and participation was facilitated [3][4] - The voting results will be filed on SEDAR and made available on the company's website [20] Q&A Session All Questions and Answers - No specific questions were raised during the meeting regarding the motions presented [12][15][18][22]

Insteel Industries (NYSE:IIIN) Q1 2026 Earnings call January 15, 2026 10:00 AM ET Company ParticipantsH. O. Woltz - CEOScot Jafroodi - VP, CFO and TreasurerConference Call ParticipantsJulio Romero - Equity AnalystTyson Bauer - Senior AnalystOperatorHello and welcome everyone to the Insteel Industries First Quarter 2026 earnings call. My name is Becky, and I will be your operator today. All lines will be muted throughout the presentation portion of the call, with a chance for Q&A at the end. If you wish to a ...

Viemed Healthcare (NasdaqCM:VMD) FY Conference January 15, 2026 10:00 AM ET Company ParticipantsJoe Dorame - Managing DirectorTodd Zehnder - COOCasey Hoyt - CEOJoe DorameHello and welcome to the VieMed Healthcare Fireside Chat. My name is Joe Dorame, Managing Partner at Lytham Partners, and today I will be moderating a Q&A discussion with Casey Hoyt, Chief Executive Officer, and Todd Zehnder, Chief Operating Officer at VieMed, which trades on the Nasdaq under the ticker VMD. Let's get started. Casey and Tod ...